Who should not use peptides: the screening list

Most peptide writing is about who might benefit. This page is about who shouldn’t start at all. Three situations rule peptides out: active or recent cancer, pregnancy or breastfeeding, and a known allergy to the compound or what it’s mixed with. Another group of conditions isn’t an automatic no, but it isn’t a do-it-yourself decision either.

Nothing here is a substitute for a doctor who knows your history. What we can do is show where each item on the list comes from. For the handful of peptides that are licensed medicines, the reasons are written into the official prescribing information, and those labels are the best evidence available for the unlicensed relatives that share their mechanism.

Why we lean on drug labels

Unlicensed peptides have almost no formal safety data in people. A 2026 review of BPC-157 counted fewer than 30 human participants across three uncontrolled pilot studies, and no validated formulation [9]. You can’t build a contraindication list from that.

Licensed peptide drugs are different. Semaglutide, somatropin (growth hormone), tesamorelin (a growth-hormone-releasing hormone analogue), mecasermin (IGF-1) and bremelanotide all went through full trial programmes, and their labels spell out who must not take them [1–5]. When an unlicensed peptide works on the same system, it is reasonable to assume at least the same exclusions apply. It may need more, because nobody has looked.

The absolute no-gos

Active cancer, or cancer that hasn’t finished treatment

This is the clearest line on the list. The growth-hormone-axis labels are blunt about it. Somatropin is contraindicated “in the presence of active malignancy”, and the label says any earlier cancer should be inactive, with treatment complete, before starting [2]. Tesamorelin carries the same contraindication and warns that it raises IGF-1, a growth factor whose long-term effects at raised levels are unknown [3]. Mecasermin, which is IGF-1 itself, is contraindicated in children with malignant neoplasia or a history of it [4].

The repair peptides raise a related worry by a different route. BPC-157 increased blood-vessel growth in a chick-embryo assay, in cultured human endothelial cells and in the ischaemic hind limbs of rats, working through the VEGFR2 receptor [6]. Thymosin beta-4, the parent molecule of TB-500, promoted blood-vessel sprouting in cell and tissue assays, driven by a short seven-amino-acid stretch [7]. Laboratory and animal work has also tied the beta-thymosin family to tumour cell migration and metastasis [8].

None of that proves either peptide causes or feeds cancer in people. No one has studied it. But new blood-vessel growth is something a tumour needs, and we would not want a compound chosen for that property anywhere near one.

Pregnancy and breastfeeding

Every relevant label treats pregnancy as a stop. Tesamorelin is formally contraindicated in pregnancy; in rats it caused hydrocephaly in offspring at roughly two to four times the clinical exposure [3]. The semaglutide label tells people using it for weight loss to stop when pregnancy is recognised, to stop at least two months before a planned pregnancy because the drug lingers, and advises against breastfeeding on the tablet form [1]. Bremelanotide’s label advises effective contraception and stopping if pregnancy is suspected, after fetal harm in dogs and mice [5].

For unlicensed peptides there is simply no human pregnancy data. That absence is the answer.

A known allergy to the peptide or its excipients

Serious hypersensitivity, including anaphylaxis, is listed as a contraindication or warning on the semaglutide, tesamorelin, mecasermin and somatropin labels [1–4]. The practical problem with research-grade products is that you often can’t tell what the excipients are. When researchers bought semaglutide vials from illegal online pharmacies, every sample contained endotoxin (bacterial debris that can trigger fever and inflammation), and the labels and packaging failed most of the visual-quality criteria they checked [10].

Conditions that need a specialist conversation first

These aren’t automatic exclusions. They change which compounds are suitable, if any, and how closely someone needs watching.

Two items from our own screening list don’t have a label to point to. Poorly controlled autoimmune disease is on it because several popular peptides are sold as immune modulators, and pushing an unstable immune system in an unknown direction is a poor bet. Blood thinners and immunosuppressants are on it because interactions depend on the specific compound and nobody has tested them. Those two are precautionary judgements, not findings.

What a proper screen looks like

A prescriber starting any of the licensed drugs above would take a full history, check it against the contraindications, and usually arrange baseline blood tests: glucose for the growth-hormone-axis drugs, kidney function where dehydration is a risk [1–3]. They would then review early, compare later results with that baseline, and agree in advance what would make them stop.

That structure is worth expecting from anyone involved in your care. If someone is willing to supply an injectable compound without asking a single question about your health, that tells you how seriously they take the rest of the process.

What we still don’t know

• Whether any unlicensed repair peptide changes cancer risk in people. The worry rests on mechanism and animal work, not human data.
• Whether the label warnings for licensed drugs fully cover their unlicensed relatives. They may understate the risk, since the unlicensed compounds have had far less testing.
• How peptides interact with common medicines, including anticoagulants. No interaction studies exist for most of them.
• What is actually in a given research-grade vial, which matters most for anyone with allergies.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.